Delivery Timing in Morbidly Adherent Placentas: a Randomized, Controlled Trial

Placenta Accreta Clinical Trial

— MAP  

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02635412
• Other study ID #: HSC-MS-16-0085
• Status: Withdrawn
• Phase: N/A
• Start date: March 2016
• Est. completion date: March 2018

Study information

• Verified date: July 2018
• Source: The University of Texas Health Science Center, Houston
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized controlled trial to investigate the optimal timing of delivery in clinically stable women with a suspected morbidly adherent placenta.

Description:

This is a randomized controlled trial to investigate the optimal timing of delivery in clinically stable women with a suspected morbidly adherent placenta dispositioned for a scheduled delivery. The primary outcome will be assessed by comparing the composite neonatal morbidity and composite maternal morbidity between the two groups (delivery at 34 versus 36 weeks gestational age).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 2018
• Est. primary completion date: March 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Women with monographically morbidly adherent placenta with or without a placenta previa.

• Scheduled delivery via cesarean hysterectomy

Exclusion Criteria:

• Delivery planned prior to 36 weeks (e.g. non-reassuring fetal status, preterm labor, severe preeclampsia, other medical/fetal indication for delivery as determined by the managing physician).

Related Conditions & MeSH terms

• Morbidly Adherent Placenta
• Placenta Accreta

Intervention

Other:
• Scheduled timing of delivery

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
The University of Texas Health Science Center, Houston

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite neonatal morbidity		Within 72 hours of newborn discharge
Primary	Maternal neonatal morbidity		Within 72 hours of patient discharge